L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Clinical trial NCT04924413 · TERMINATED

Trial details

NCT number: NCT04924413
Sponsor: Quanli Gao
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Malignant Melanoma

Start date: 2021-07-01
Primary completion: 2024-07-02
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.